Monitor measures early signs of pulmonary oedema:
This article was originally published in Clinica
Executive Summary
Israeli company RS Medical Monitoring has developed a device to monitor patients for early signs of pulmonary oedema, a potentially fatal complication associated with acute heart disease. The monitor, which measures changes in the active resistance in the lungs caused by an accumulation of fluids, gives an audio-visual signal if the fluid level exceeds or falls below pre-set levels.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.